<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">8211617</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6714</journal-id>
<journal-id journal-id-type="nlm-ta">Prog Neuropsychopharmacol Biol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Prog. Neuropsychopharmacol. Biol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Progress in neuro-psychopharmacology &amp; biological psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">0278-5846</issn>
<issn pub-type="epub">1878-4216</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">30149092</article-id>
<article-id pub-id-type="pmc">6249083</article-id>
<article-id pub-id-type="doi">10.1016/j.pnpbp.2018.08.021</article-id>
<article-id pub-id-type="manuscript">NIHMS1505763</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>The role of ARID1B, a BAF chromatin remodeling complex subunit, in neural development and behavior</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Moffat</surname>
<given-names>Jeffrey J.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Jung</surname>
<given-names>Eui-Man</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ka</surname>
<given-names>Minhan</given-names>
</name>
<xref ref-type="aff" rid="A3">c</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Amanda L.</given-names>
</name>
<xref ref-type="aff" rid="A2">b</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jeon</surname>
<given-names>Byeong Tak</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Santen</surname>
<given-names>Gijs W. E.</given-names>
</name>
<xref ref-type="aff" rid="A4">d</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kim</surname>
<given-names>Woo-Yang</given-names>
</name>
<xref ref-type="aff" rid="A1">a</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>a</label>Department of Biological Sciences, Kent State University, Kent, OH 44242, USA</aff>
<aff id="A2"><label>b</label>University of Nebraska Medical Center, Omaha, NE 68198, USA</aff>
<aff id="A3"><label>c</label>Research Center for Substance Abuse Pharmacology, Korea Institute of Toxicology, Daejeon, Republic of
Korea</aff>
<aff id="A4"><label>d</label>Department of Clinical Genetics, Leiden University Medical Center, Leiden, Netherlands</aff>
<author-notes>
<corresp id="CR1"><label>*</label><bold>Corresponding author</bold>: Woo-Yang Kim, Ph.D., <email>wkim2@kent.edu</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>4</day>
<month>9</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>24</day>
<month>8</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<day>08</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>08</day>
<month>3</month>
<year>2020</year>
</pub-date>
<volume>89</volume>
<fpage>30</fpage>
<lpage>38</lpage>
<!--elocation-id from pubmed: 10.1016/j.pnpbp.2018.08.021-->
<abstract id="ABS1">
<p id="P1">Haploinsufficiency of the chromatin remodeling factor <italic>ARID1B</italic> leads to autism spectrum disorder and
intellectual disability. Several independent research groups, including our own, recently examined the effects of heterozygous
deletion of <italic>Arid1b</italic> in mice and reported severe behavioral abnormalities reminiscent of autism spectrum disorders
and intellectual disability as well as marked changes in gene expression and decreased body size. <italic>Arid1b</italic>
heterozygous mice also display significant cortical excitatory/inhibitory imbalance due to altered GABAergic neuron numbers and
impaired inhibitory synaptic transmission. Abnormal epigenetic modifications, including histone acetylation and methylation, are
additionally associated with <italic>Arid1b</italic> haploinsufficiency in the brain. Treating adult <italic>Arid1b</italic>
mutant mice with a positive GABA allosteric modulator, however, rescues multiple behavioral abnormalities, such as cognitive and
social impairments, as well as elevated anxiety. While treating <italic>Arid1b</italic> haploinsufficient mice with recombinant
mouse growth hormone successfully increases body size, it has no effect on aberrant behavior. Here we summarize the recent
findings regarding the role of ARID1B in brain development and behavior and discuss the utility of the <italic>Arid1b</italic>
heterozygous mouse model in neurodevelopmental and psychiatric research. We also discuss some of the opportunities and potential
challenges in developing translational applications for humans and possible avenues for further research into the mechanisms of
ARID1B pathology in the brain.</p>
</abstract>
<kwd-group>
<kwd>ARID1B</kwd>
<kwd>autism</kwd>
<kwd>intellectual disability</kwd>
<kwd>neural progenitor</kwd>
<kwd>brain development</kwd>
<kwd>interneuron</kwd>
<kwd>GABA intervention</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>